We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Brain Tumors Grow by Tapping Preexisting Blood Vessels for Nutrients

By LabMedica International staff writers
Posted on 24 Aug 2014
Findings from a new study on how tumors grow and spread in the brain may cause cancer researchers to rethink treatment options based on drugs that block angiogenesis.

According to the angiogenesis theory, tumors that are more than one cubic millimeter in size need to attract or grow their own blood vessels to survive. More...
This theory led to clinical trials with anti-angiogenesis drugs such as bevacizumab and DC101. However, such clinical trials have failed to produce evidence of reduced tumor growth or increased patient survival.

Investigators at the University of Michigan (Ann Arbor, USA) examined this phenomenon in rodents and human cancer patients and by advanced computer modeling.

They reported in the July 2014 issue of the journal Neoplasia that implanted rodent and human brain cancer cells commonly invaded and proliferated within the brain perivascular space. This form of brain tumor growth and invasion was also shown to characterize de novo generated endogenous mouse brain tumors, biopsies of primary human glioblastoma, and peripheral cancer metastasis to the human brain.

Perivascularly invading brain tumors became vascularized by normal brain microvessels when individual glioma cells used perivascular space as a conduit for tumor invasion. Since the cancer cells were obtaining blood from already existing vascular tissues, their growth and spread were not impeded by treatment with antiangiogenic agents.

The experimental findings showing that tumor perivascular spreading was independent of growth of new blood vessels had been predicted by computational modeling. The investigators tested this prediction experimentally by blocking angiogenic signaling using antibodies targeting the VEGF-A (vascular endothelial growth factor) signaling axis. VEGF-A inhibitors failed to block progressive tumor growth or extend median survival in multiple brain tumor models.

"The key question has been to determine how tumor-generating cells grow to form the macroscopic tumor mass that eventually kills the patients," said senior author Dr. Pedro Lowenstein, professor of neurosurgery and cell and developmental biology at the University of Michigan. "We have shown that because of the very high density of endogenous vessels in the brain and central nervous system, the cells grow along those preexisting vessels and eventually divide to fill the space between them, where the distance between any two vessels is very small. This iterative growth along vessels and into the space between means the tumor does not grow like a balloon requiring new vessels to grow into its expanding mass to rescue it, but rather as an accumulation of local small masses which then coalesce into a large tumor."

Related Links:

University of Michigan



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.